This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the data on Otsuka & Lundbeck's recently approved Rexulti (brexpiprazole) for patients with Alzheimer's dementia.
Ticker(s): OTSKYWho's the expert?
Institution: Mount Sinai
- Professor of neurology and psychology, associate director of the Mount Sinai Alzheimer's disease research center, and Chairman Emeritus of the National Medical and Scientific Advisory Council of the Alzheimer's Association.
- Currently manages 200 patients with Alzheimer's dementia.
- Discovered the first drugs that could lower amyloid formation in Alzheimer's disease. Current research focuses on amyloid metabolism, CTE diagnosis, and new classes of drugs for treating PTSD.
Interview GoalTo discuss the standard of care and the potential of Otsuka and Lundbeck’s drug Rexulti (brexpiprazole) for agitation associated with Alzheimer’s dementia (AAD) including the Phase 3 clinical trial data of brexpiprazole in patients with Alzheimer's dementia presented at the 2022 Alzheimer's Association International Conference.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
